Companies: 49,246 Total Market Cap: 132416288817079.32

Telix Pharmaceuticals Limited

ASX-TLX
Healthcare Biotechnology
Rank #2978
Market Cap 5.50 B
Volume 1.03 M
Price 16.27
Change (%) 1.52%
Country or region Australia Australia

Telix Pharmaceuticals Limited's latest marketcap:

5.50 B

As of 05/20/2025, Telix Pharmaceuticals Limited's market capitalization has reached $5.50 B. According to our data, Telix Pharmaceuticals Limited is the 2978th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 5.50 B
Revenue (ttm) 502.82 M
Net Income (ttm) 32.05 M
Shares Out 338.11 M
EPS (ttm) 0.09
Forward PE 57.94
Ex-Dividend Date n/a
Earnings Date 05/22/2025
Market Cap Chart
Data Updated: 05/20/2025

Telix Pharmaceuticals Limited's yearly market capitalization.

Telix Pharmaceuticals Limited has seen its market value grow from A$1.06 B to A$8.57 B since 2020, representing a total increase of 708.64% and an annual compound growth rate (CAGR) of 61.06%.
Date Market Cap Change (%)
05/20/2025 A$8.57 B 0.4%
12/31/2024 A$8.24 B 152.44%
12/29/2023 A$3.26 B 41.89%
12/30/2022 A$2.30 B 4.1%
12/31/2021 A$2.21 B 108.44%
12/31/2020 A$1.06 B

Company Profile

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company specializing in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases. The company operates in key markets including Australia, Belgium, Japan, Switzerland, and the United States.

Key Products

  • Illuccix – A treatment for prostate cancer.
  • TLX66-CDx – Used for imaging osteomyelitis.

Product Pipeline

Telix Pharmaceuticals has a robust pipeline of innovative candidates targeting various cancers and rare diseases:

  • TLX591 – A radio antibody-drug conjugate for prostate cancer.
  • TLX250-CDx – For the treatment and diagnosis of renal (kidney) cancer.
  • TLX101-CDx – Targets brain (glioma) cancer.
  • TLX66-CDx – Designed for bone marrow conditioning.
  • TLX300-CDx – For soft tissue sarcoma diagnosis and treatment.
  • TLX250 – Focused on clear cell renal cell carcinoma.
  • TLX101 – A glioblastoma (brain cancer) therapy.
  • TLX66 – For bone marrow conditioning.
  • TLX300 – Targets soft tissue sarcoma.
  • TLX592 – A prostate cancer therapy candidate using targeted alpha therapy.

Company Background

Founded in 2015, Telix Pharmaceuticals Limited is headquartered in North Melbourne, Australia.

Frequently Asked Questions

As of 05/20/2025, Telix Pharmaceuticals Limited (including the parent company, if applicable) has an estimated market capitalization of $5.50 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Telix Pharmaceuticals Limited global market capitalization ranking is approximately 2978 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Australia
Founded 2015
IPO Date n/a
Employees 234
CEO Christian Behrenbruch
Sector Healthcare
Industry Biotechnology
Address 55 Flemington Road
North Melbourne, VIC 3051
Australia
Website https://telixpharma.com
People Also Watch
VRTX
445.19 1.52%
CSL Limited
156.67 1.52%
REGN
610.63 1.52%
KRX-207940
732.25 1.52%